Fiche publication
Date publication
août 2026
Journal
Molecular cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Pr VIGNAUD Jean-Michel
Tous les auteurs :
Sexton-Oates A, Mathian É, Candeli N, Lim Y, Voegele C, Di Genova A, Mangé L, Li Z, van Weert T, Kalson L, Delhomme TM, Hillen LM, Blázquez-Encinas R, Gonzalez-Perez A, Morrison ML, Lauricella E, Mangiante L, Bonheme L, Moonen L, Absenger G, Altmuller J, Degletagne C, Brustugun OT, Cahais V, Centonze G, Chabrier A, Cuenin C, Damiola F, de Montpréville VT, Deleuze JF, Dingemans AC, Fadel É, Gadot N, Ghantous A, Graziano P, Hofman P, Hofman V, Ibáñez-Costa A, Lacomme S, Lopez-Bigas N, Lund-Iversen M, Milione M, Muscarella LA, Pedraza-Arevalo S, Perrin C, Planchard G, Popper H, Roz L, Sparaneo A, Buikhuisen W, van den Berg J, Tesselaar M, Kim J, Speel EJM, Tabone-Eglinger S, Walter T, Wright GM, Castaño JP, Chalabreysse L, Chen L, Caux C, Volante M, Girard N, Vignaud JM, Conde E, Mansuet-Lupo A, Brcic L, Pelosi G, Papotti MG, Lantuejoul S, Derks J, Dayton T, Alcala N, Foll M, Fernandez-Cuesta L
Lien Pubmed
Résumé
Lung neuroendocrine tumours (NETs, also known as carcinoids) are rapidly rising in incidence worldwide but have unknown aetiology and limited therapeutic options beyond surgery. The current WHO classification, based on mitotic count and presence or absence of necrosis, divides lung NETs into grade-1 typical, and grade-2 atypical tumours. This dichotomous classification however does not account for recently described molecular entities nor is it sufficient for clinical management.
Mots clés
Cancer, Deep-learning, Genomics, Multi-omics, Pulmonary carcinoids
Référence
Mol Cancer. 2026 08 27;25(1):
